7 Best Stocks to Buy for Short Term
In a continuously evolving market, investing has become a game of timing and informed decision-making.
Corcept Therapeutics Inc (CORT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bayforest Capital Theodoros Tsagaris | 233 | $9,392 | -96% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $33.56 | 24,218 | $812,836.00 | 1,146,631 | 2026-03-17 | Filing | |
| $33.00 | 75,782 | $2,500,972.72 | 1,122,413 | 2026-03-17 | Filing | |
| $21.53 | 100,000 | $2,153,000.00 | 3,308,303 | 2021-06-11 | Filing | |
| $21.53 | 50,000 | $1,076,500.00 | 1,046,838 | 2021-06-11 | Filing | |
| $22.64 | 68 | $1,539.52 | 3,208,303 | 2020-12-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $40.97 | 20,000 | $819,400.00 | 2,231 | 2026-04-07 | Filing | |
| $50.07 | 26,198 | $1,311,825.55 | 2,918,326 | 2026-03-25 | Filing | |
| $36.01 | 11,767 | $423,729.67 | 2,231 | 2026-03-20 | Filing | |
| $35.99 | 8,233 | $296,346.01 | 2,231 | 2026-03-04 | Filing | |
| $40.87 | 20,000 | $817,334.00 | 1,235 | 2026-02-03 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 68,625 | $2,766,274 | 0.34% | |
| 2. | 61,250 | $2,468,988 | 0.24% | |
| 3. | 31,000 | $1,249,610 | 0.26% | |
| 4. | 17,251 | $695,388 | 0.06% | |
| 5. | 13,166 | $530,721 | 0.03% |
News See All
Corcept Therapeutics (CORT) Climbs 19.7% as Lifyorli Gets FDA OK
Corcept Therapeutics rallied for a second day on Wednesday, soaring 19.66 percent to finish at $40.47 apiece, as investors snapped up shares after securing the green light of the Food and Drug Administration...
10 Stocks Investors Are Buying Now: Chewy, Braze, Sarepta, and More
The company said that it has begun recruiting highly-skilled German talent to operationalize its upcoming satellite manufacturing facility in Berlin, as part of its plan to double the production capacity...
H.C. Wainwright Cuts Corcept Therapeutics Incorporated (CORT) Price Target, Keeps Buy Rating
The company reported Q4 2025 revenue of $202.1 million, which fell short of the consensus estimate of $254.9 million.
12 Best Under-the-Radar Stocks to Buy According to Hedge Funds
On March 6, Reuters reported that US and European stock markets ended a volatile week with losses of over 1% as rising geopolitical tensions pushed oil prices higher.
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q4 2025 Earnings Call Transcript
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q4 2025 Earnings Call Transcript February 24, 2026Corcept Therapeutics Incorporated misses on earnings expectations.
Is Corcept Therapeutics Incorporated (CORT) at an inflection point?
Polen Capital, an investment management company, released its fourth-quarter investor letter for “Polen 5Perspectives Small Growth Strategy”. A copy of the letter can be downloaded here.
FDA-Issued CRL for Relacorilant NDA Leads to Bullish Views Around Corcept Therapeutics (CORT)
On February 2, Edward Nash from Canaccord Genuity reaffirmed his Buy rating for Corcept Therapeutics (NASDAQ:CORT).
17 Biotechnology Stocks with More Than 50% Upside
2025 was a year characterized by both challenges and opportunities for the biotechnology sector.
Corcept Therapeutics (CORT) Climbs 26.6% on Stellar Clinical Trial Result
Corcept Therapeutics saw its share prices jump by 26.6 percent week-on-week, as investors took heart from the strong clinical trial results of its drug candidate, relacorilant, in patients with platinum...
Hedge Fund Resource Center